この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2004/8/21 分で読めます
Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use; Proposed Amendment of Final Monograph for Over-the-Counter Nasal Decongestant Drug Products
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA) is proposing to amend the final monograph for over-the-counter (OTC) nasal decongestant drug products (drug products used to relieve nasal congestion due to a cold, hay fever, or other upper respiratory allergies) to remove the indication "for the temporary relief of nasal congestion associated with sinusitis" and to prohibit use of the terms "sinusitis" and "associated with sinusitis" elsewhere on the labeling. This proposal is part of FDA's ongoing review of OTC drug products.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →